Fig. 5
From: Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
Proportion of patients with A maximum pain NRS score of 0 or 1 during the last 28 days before the last study dose, and B mean reduction in pain NRS score of > 50% from baseline to the last 28 days before the last study dose. Percentages are based on the number of patients with a maximum NRS score ≥ 4 at baseline. ***P < .001. NRS numerical rating scale, ns non-significant